Linc AB
STO:LINC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Linc AB
STO:LINC
|
SE |
|
Cutera Inc
NASDAQ:CUTR
|
US |
|
Hannover Rueck SE
XETRA:HNR1
|
DE |
|
SingSong Holdings Co Ltd
KRX:006880
|
KR |
|
agilon health inc
NYSE:AGL
|
US |
Linc AB
Linc AB is an investment company that focuses on long-term share ownership in the Nordic life science market. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2021-05-28. Linc invests in product-oriented companies within the Nordic Life Science industry - primarily in pharmaceutical and medical technology companies. The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an earlier phase compared to investments in medical technology. Linc Invest is an active and long-term owner with a wide industrial network to support the portfolio companies. The firm works together with the management, founders and board to realize the inherent potential that exists in the investment, have ambitious plans for further development and expansion and actively participate in the nomination committee work.
Linc AB is an investment company that focuses on long-term share ownership in the Nordic life science market. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2021-05-28. Linc invests in product-oriented companies within the Nordic Life Science industry - primarily in pharmaceutical and medical technology companies. The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an earlier phase compared to investments in medical technology. Linc Invest is an active and long-term owner with a wide industrial network to support the portfolio companies. The firm works together with the management, founders and board to realize the inherent potential that exists in the investment, have ambitious plans for further development and expansion and actively participate in the nomination committee work.
